Results 131 to 140 of about 6,421 (186)

Clinical Characteristics and Treatment Efficacy in Patients With SARS-CoV-2 Positivity After Nirmatrelvir-Ritonavir Therapy. [PDF]

J Med Virol
Yang H, Gao L, Xue Y, Zhang Z, Guan L, Zhang H, Ma H, Li X, Li J, Tong Z.   +9 more
europepmc   +1 more source

Unexpected voriconazole toxicity due to nirmatrelvir/ritonavir: a case report on drug-drug interaction and the role of therapeutic drug monitoring. [PDF]

Front Pharmacol
López-Hernández J, Guisado-Gil AB, Mejías-Trueba M, Herrera-Hidalgo L, Reina-Martínez FJ, Gil-Navarro MV.   +5 more
europepmc   +1 more source

Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19. [PDF]

N Engl J Med
Hammond J, Yunis C, Fountaine RJ, Luscan G, Burr AM, Zhang W, Wisemandle W, Soares H, Baniecki ML, Hendrick VM, Kalfov V, Pypstra R, Rusnak JM.   +12 more
europepmc   +1 more source

Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19. [PDF]

BMC Infect Dis
Xu P, Zhang L, Wu Q.
europepmc   +1 more source

Paxlovid-induced Tacrolimus Toxicity in a Renal Transplant Recipient [PDF]

Doughty, Reece
core  

Hospitalizations and Mortality Among Older Adults With and Without Restricted Access to Nirmatrelvir-Ritonavir.

JAMA
Mafi JN, Vangala S, Kapral MK, Wu PE, Cui M, Romanov A, Kahn KL.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Nirmatrelvir+ritonavir

Reactions Weekly, 2023
  +7 more sources

Nirmatrelvir+ritonavir/tacrolimus

Reactions Weekly, 2023
  +9 more sources